Canaan Partners Closes $650 Million Fund, Canaan VIII

Share Article

Global firm marks 20th anniversary with closing of eighth fund bringing capital under management to $3B.

Canaan Partners, a multibillion-dollar global venture capital firm, announced today the closing of the $650 million fund, Canaan VIII. Consistent with previous funds, the new fund will focus on building next generation market-leaders in both the technology and healthcare sectors and brings Canaan Partners' total capital under management to $3 billion.

With a 20-year track record as one of the premier investors in innovative early-stage technology and healthcare companies worldwide, the creation of the new fund will enable the firm to continue its strategy of taking active and significant ownership positions in pioneering companies in the digital media, communications, enterprise, clean technology, biopharmaceutical, medical device and diagnostics sectors. In addition, the larger fund will facilitate Canaan's sustained, global expansion by committing up to 25 percent of the fund to international investments.

Canaan also announced today the promotion of Dr. Stephen Bloch to general partner at the firm. Having been an entrepreneur and practicing physician, Dr. Stephen Bloch joined Canaan in 2002 and knows first hand the challenges of building successful healthcare companies. Dr. Bloch led Canaan's investment in Amicus Therapeutics (FOLD), a clinical-stage biopharmaceutical company developing next-generation oral therapies for the management of genetic diseases; he also sits on the boards of Advanced Biohealing, a developer of regenerative wound healing therapies, and Marinus Pharmaceuticals, a leader in development of drugs to treat serious neurological disorders. Dr. Bloch joins existing general partners: Brent Ahrens, John Balen, Wende Hutton, Maha Ibrahim, Deepak Kamra, Guy Russo and Eric Young.

Canaan plans to begin investing fund VIII this year. The firm typically leads its deals and maintains double-digit ownership stakes. Canaan's previous funds have resulted in more than 120 positive exits, including 53 IPOs. The firm has launched numerous market leaders and disrupters, such as SuccessFactors, the global leader in on-demand performance management solutions which went public this past November on Nasdaq; Acme Packet, maker of VoIP equipment for carriers and one of the top-10 performing tech IPOs of 2006; DoubleClick, the leading online advertising solution acquired by Google; Cerexa, one of the largest private biotech acquisitions in history; and Dexcom, the largest diagnostic IPO of 2005.

"For 20 years, Canaan has been helping innovative technology and healthcare companies achieve exceptional growth and success; the additional capital in Fund VIII will allow Canaan to seek out new, exciting companies and noteworthy entrepreneurs across the globe," said Deepak Kamra, general partner at Canaan. "In addition to our Silicon Valley base, we have key personnel on the ground in India, Israel and the New York corridor and have already made significant investments in these regions."

Fund VIII will continue Canaan's focus on digital media investments, both in its Silicon Valley base where it has funded publishing industry-disruptors such as Blurb, and as well as in the New York corridor, where the firm has already funded digital media front-runners, such as Tremor Media, the largest pure-play video ad network; Associated Content, a leading publisher of user-generated content; and Peer39, a pioneer in targeted, semantic advertising solutions.

With its healthcare investments, Canaan has enjoyed 9 positive exits in 3 years and will continue to focus on biopharmaceutical companies with a special emphasis on combating infectious diseases, such as VaxInnate, developer of novel vaccines for pandemic and seasonal influenza; medical device companies developing next generation devices for the treatment of treat chronic and major diseases, such as ReVision Optics (RVO) whose technology corrects vision lost through the natural aging process (presbyopia); and diagnostics that are tied to specific, personalized therapies, such as Transoma Medical, a leading provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease. "We deliver superior company-building expertise to entrepreneurs, which in turn generates attractive returns for our limited partners," said Brent Ahrens, general partner at Canaan. "We will continue to execute on our proven investment strategy on a global scale."

The larger fund will also allow the firm to expand its reach in India and in Israel, countries in which the firm has actively been investing via local offices. Canaan has demonstrated early momentum in these areas with key investments in companies such as BharatMatrimony, the world's largest consumer Internet site for matrimonial services based in India; and LiveU, an innovative provider of mobile video broadcasting technology from Israel.

About Canaan Partners
Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies. For 20 years, they have taken an active and committed role in the companies in which they invest, and have completed more than 69 mergers and acquisitions and 53 IPOs. With $3 billion under management and a worldwide footprint, the firm's technology team is committed to catalyzing the growth of innovative companies in the digital media, communications & mobility, enterprise and clean tech industries. Among its successes are DoubleClick, the leading online advertising solution, Match.com, the most popular online dating site in the world, CommerceOne, the company that pioneered B2B ecommerce; Capstone Turbine, first to market and world's leading producer of commercially viable microturbine energy products; and VOIP equipment supplier Acme Packet, which was one of the top ten performing tech IPOs of 2006. Other Canaan technology investments include Active Networks, BharatMatrimony, Blurb, Cortina, GroundWorks, ID Analytics, Tremor Media and SuccessFactors. Canaan has offices in California, Connecticut, India and Israel. For more information visit: http://www.canaan.com.

Contact
Erin McMahon-Lyman
Marketing Alchemist
erin@marketingalchemist.com
Phone (415) 307-9962

Gina Vakili
Canaan Partners
gvakili@canaan.com
Phone (650) 854-8092

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gina Vakili
Visit website